Pharmacy Benefit Managers

The Federal Trade Commission (FTC) has launched a major investigation against three of the nation's largest pharmacy benefit managers (PBMs) for allegedly inflating insulin prices, leaving patients across the U.S. facing exorbitant costs for the life-saving medication. The targeted PBMs, CVS Health’s Caremark Rx, Cigna’s Express Scripts, and UnitedHealth Group’s OptumRx, are accused of creating a pricing system that prioritizes profit over patient care.

https://youtu.be/UNwB2Kcao0k

According to the FTC, the companies orchestrated a scheme that significantly raised the list prices for insulin by favoring higher. . .

You have exceeded the number of free content views. To continue viewing exclusive JudgeNap content, you'll need a subscription. Please choose your subscription plan here.

Already a member? Login here.

A bipartisan coalition of 39 attorneys general, led by North Carolina Attorney General Josh Stein, is intensifying efforts to address the soaring costs of prescription drugs. The coalition is urging Congress to pass legislation aimed at increasing transparency in the pharmaceutical industry, particularly targeting pharmacy benefit managers (PBMs).

The attorneys general from 39 states are collectively advocating for legislative measures that would compel PBMs to enhance transparency in their operations. PBMs play a crucial role in creating lists of prescription medications covered by insurance plans, determining the accessibility and affordability of drugs for patients.

The coalition contends that PBMs have. . .

You have exceeded the number of free content views. To continue viewing exclusive JudgeNap content, you'll need a subscription. Please choose your subscription plan here.

Already a member? Login here.

FTC Takes Action Against Pharmacies Inflating Insulin Prices

Bipartisan Coalition of Attorneys General Advocates for Drug Cost Transparency Legislation

Queue